Since the company’s foundation in 1993, Hetero has clearly come a long way. What were the key success factors at that time, which laid the groundwork…
In Conversation
Over the years, multinational corporations (MNCs) have increasingly been penetrating the Indian pharmaceutical markets. How have you observed this trend throughout your career? Based on India’s…
India is clearly a new location for Cockram, and what brought you here was your loyal customer Pfizer. After 3 years of project work, a permanent…
“ "The long-term strategy consists in looking at partnerships and co-marketing rights for certain molecules with large companies." ”
Having been director here in India between 1998-2002, and then again since 2006, you have clearly been in the front seat to observe the evolution of…
Looking back at the company’s recent challenges, we see a very tough 2009, largely due to the Betapharm acquisition and the subsequent changes in German regulations.…
You spent two decades in the US as an academic, executive, and entrepreneur, and then left to return to China and found AbMax. What’s the story…
It seems like there’s a lot to be happy about here: Pfizer is ranked number 1 multinational R&D-based biopharmaceutical company in China, where you also have…
The Chamber recently released this year’s European Business in China Business Confidence Survey – what were some of its key takeaways? There are four main points…
Mr. Agana, you have been in Pharex HealthCorp for more than twenty years. Can you give to our readers an overview of Pharex and what have…
Can you please start by giving to our readers an overview of your background and your involvement with Janssen? I am a Public Health graduate and…
Servier was one of the first pharmaceutical companies to establish a presence in China back in 1979. How has Servier’s presence evolved alongside China’s huge transformations…
